Prestige Consumer Healthcare (NYSE:PBH) Shares Gap Up – Time to Buy?

Prestige Consumer Healthcare Inc. (NYSE:PBH) gapped up before the market opened on Friday . The stock had previously closed at $60.06, but opened at $61.95. Prestige Consumer Healthcare shares last traded at $61.4020, with a volume of 168,459 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PBH. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Jefferies Financial Group cut their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Three research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $80.60.

Prestige Consumer Healthcare Stock Up 1.3%

The firm’s fifty day simple moving average is $65.89 and its two-hundred day simple moving average is $63.36. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $2.88 billion, a price-to-earnings ratio of 16.14, a price-to-earnings-growth ratio of 1.91 and a beta of 0.41.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The firm had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. During the same quarter in the prior year, the business earned $1.22 EPS. The firm’s quarterly revenue was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the sale, the vice president owned 41,048 shares in the company, valued at $2,706,294.64. The trade was a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.40% of the stock is owned by corporate insiders.

Institutional Trading of Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently bought and sold shares of the stock. UMB Bank n.a. lifted its position in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after buying an additional 219 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at about $29,000. First Horizon Corp acquired a new stake in shares of Prestige Consumer Healthcare during the third quarter valued at about $32,000. Barrow Hanley Mewhinney & Strauss LLC raised its stake in shares of Prestige Consumer Healthcare by 106.8% in the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after acquiring an additional 283 shares during the period. Finally, Torren Management LLC purchased a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at approximately $35,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).